Home World News High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in... World News High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma By Ogkologos - August 20, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATRix/IELSG43 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October October 14, 2024 EMA Recommends Extension of Therapeutic Indications for Olaparib to Patients with... July 17, 2024 Makeup Artist Gives Breast Cancer Survivors Free Makeovers January 6, 2021 5 ways cancer can impact sexual wellbeing May 17, 2023 Load more HOT NEWS 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... Only a Quarter of Phase III Studies Demonstrated Improved QoL in... Avapritinib Not Superior to Regorafenib in Terms of Median PFS in... The Appraisal – Does a charity have a role in biotech...
